Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review

  title={Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review},
  author={K S Louie and Joanne M Micallef and Jeanne M Pimenta and Ulla M. Forss{\'e}n},
  journal={Journal of Viral Hepatitis},
Summary.  Thrombocytopenia (TCP) is a haematological condition known to occur in chronically infected hepatitis C (HCV) patients and may interfere with diagnostic procedures, such as liver biopsy, because of risk of bleeding. It may also exclude patients from effective antiviral treatment. We conducted a systematic literature review of articles and conference abstracts, to assess the prevalence of TCP among those with HCV and to describe demographics, liver disease stage and treatment… 

Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye

The results of this epidemiological review provide an indirect evidence that confirms the multiplicity of aetiological factors underlying the pathophysiology of thrombocytopenia in chronic hepatitis C patients and shows that up to 25% of patients treated with interferon may develop some degree of thROMbocytopsia, and this may be associated with decreased sustained virological response rates.


The frequency of thrombocytopenia in patients with Chronic Hepatitis C infection was found to be higher and patients of age more than 60 years and of child-Pugh class C affected the most.

Chronic hepatitis C-associated thrombocytopenia: aetiology and management.

  • Y. Fouad
  • Medicine, Biology
    Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • 2013
The ability to increase platelet levels could significantly reduce the need for platelet transfusions and facilitate the use of interferon-based antiviral therapy and other medically indicated treatments in patients with liver disease.


The frequency of thrombocytopenia in patients with Chronic Hepatitis C infection was found to be higher and patients of age more than 60 years and of child-Pugh class C affected the most.

Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection

Thrombocytopenia in chronic HCV infection remain a major problem, however the recent change in DAAs without IFN, as the frontline therapy for HCV, permit to avoid the dilemmas associated with initiating or maintaining IFN based anti-viral therapy.

Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease

Sofosbuvir-based DAA therapy is a highly effective and safe treatment regimen that results in the improvement of platelet count in thrombocytopenic patients, particularly in mild to moderate stages of hepatic fibrosis.

Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries

Thrombocytopaenia is one of many factors, indicative of the poor clinical state of the patient, that contributes to withholding antiviral treatment and can be considered as a modifiable factor to enable more HCV patients to receive guideline‐recommended therapy and thus improved clinical outcomes.

Effect of splenectomy on platelets associated antibodies in hepatitis C patients with thrombocytopenia

Autoimmune mechanism plays an important role in the HCV-associated thrombocytopenia and spleen is a major source of PAIgs in patients with chronic HCV infection presplenectomy.

Trends in the prevalence of thrombocytopenia among individuals iInfected with hepatitis C Virus in the United States, 1999-2008

As the HCV-infected population ages, the prevalence of thrombocytopenia is expected to rise, and this study provides limited evidence of such an effect at the national level.



Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases

AITP occurs more commonly in patients with chronic HCV infection than would be expected by chance and requires a treatment strategy different from that used in HCV-negative AITP.

Infectious causes of chronic immune thrombocytopenia.

Liver Fibrosis Is Associated with Decreased Peripheral Platelet Count in Patients with Chronic Hepatitis B and C

A decrease in peripheral platelet count may be a sign of an increase in the degree of fibrosis during the course of chronic viral hepatitis B and C and factors other than hypersplenism may play a role in this decrease.

Thrombocytopenia in liver disease

New insights into the pathophysiological mechanisms of thrombocytopenia in patients with liver disease have provided interesting clinical reflex, and novel therapies for treating throm bopoietin-mediated mechanisms seem promising in these patients, although it remains to be established whether treating thROMbocy topenia may help improve liver disease-associated coagulopathy.

Long-Term Outcome, with Monitoring of Platelet Counts, in Patients with Chronic Hepatitis C and Liver Cirrhosis after Interferon Therapy

Investigation of platelet counts was useful for determining the long-term outcome of patients who had undergone interferon (IFN) therapy and for predicting the development of HCC.

Increased incidence of anti‐cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti‐phospholipid syndrome

The data rather failed to reveal an aetiopathogenetic link between HCV and APLS, and testing for HCV in patients with APLS or follow‐up for the possibility of the development of APLS in HCV patients cannot be suggested.

Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndrom

Anticardiolipin antibodies are frequently found in patients with chronic hepatitis C and in these patients they may be implicated in the occurrence of thrombosis and in the development ofThrombocytopenia.

Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C

Fifty per cent of the patients with chronic hepatitis C circulated cryoglobulins, with preference for those with a greater impairment of liver function, as revealed by serum cholinesterase activity.

Anticardiolipin Antibodies in Patients with Chronic Hepatitis C Virus Infection: Characterization in Relation to Antiphospholipid Syndrome

No significant association was found between aCL antibodies and clinical manifestations of APS, neither was one found between the presence of other autoantibodies or cryoglobulins and that of aCL, and no cross-reactivity between a CL antibodies and HCV antigens was observed.